Avance Clinical – ClinicReady Case Study

By Avance Clinical

Tetherex Pharmaceuticals is developing a single-cycle adenoviral vector vaccine for the treatment of Covid-19.

The treatment is designed for intranasal delivery, which is expected to provide a more efficient front-line defence against Covid-19 in airway tissues, the site of virus entry into the body. The vaccine is currently undergoing safety testing in healthy volunteers.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.